Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year

Core Viewpoint - Merck & Co. is set to report Q4 2025 earnings on February 3, 2026, with Wall Street expecting earnings of $2.01 per share and revenue of $16.12 billion, indicating a 3.1% year-over-year growth. The stock has gained 13% over the past year, outperforming the healthcare sector [1]. Financial Expectations - Wall Street anticipates EPS of $2.01 and revenue of $16.12 billion, with analysts reaffirming these estimates, reflecting confidence in the company's performance despite challenges [2]. - A significant earnings beat would require EPS of at least $2.10 (4.5% above consensus) and revenue of $16.5 billion or higher [2]. Historical Performance - Merck has exceeded earnings estimates for three consecutive quarters, with an average surprise of 5.1%. The average post-earnings stock movement is 3.2%, with a notable 8.9% increase last quarter after a $0.21 beat [3]. Recent Developments - In Q3 2025, CEO Robert Davis highlighted the importance of delivering value through an innovative portfolio and securing future growth through pipeline investments, which will be tested in the upcoming quarter [4]. - On January 26, 2026, senior executives purchased $15.98 million in stock, indicating management confidence ahead of the earnings report [5]. Sales Performance - Keytruda sales reached $8.14 billion, up 10% year-over-year, while Gardasil sales fell 24% to $1.75 billion due to weak demand in China, although the decline moderated from a 55% drop in Q2 [7]. - Management raised full-year 2025 guidance to $64.5 to $65.0 billion in sales and $8.93 to $8.98 in non-GAAP EPS, signaling confidence in Q4 execution [7]. Potential Stock Movements - Bull case triggers include EPS above $2.10 and 2026 guidance indicating sustained Keytruda growth above 8%, while Gardasil sales exceeding $1.8 billion would suggest stabilization in China demand [8]. - Bear case triggers include revenue falling below $16.0 billion, particularly if driven by weakness in Keytruda [6]. Analyst Sentiment - Analysts from major firms have raised price targets, with an average target of $114.53 implying a 10.9% upside from current levels around $111. However, Cantor Fitzgerald maintains a neutral rating, expecting near-term guidance to fall below Wall Street estimates [10]. Key Metrics - Analysts expect Keytruda sales for Q4 to be between $7.8 to $8.0 billion, with a focus on 2026 guidance. Growth projections below 8% for Keytruda would indicate peak sales approaching sooner than expected, while guidance above 10% would suggest a longer growth trajectory [11]. Valuation Context - Merck trades at 9.13x forward earnings, significantly lower than Johnson & Johnson's 16.42x and Eli Lilly's 27.17x, reflecting investor concerns about Keytruda's long-term growth and limited near-term pipeline visibility [12]. Management Expectations - The key question is whether management can demonstrate that the $3 billion optimization initiative is successfully funding pipeline development while maintaining margins, with elevated expectations for another strong quarter and confident 2026 guidance [13].